Supplement encyclopedia

Bacillus coagulans

Bacillus coagulans is a bacterium added to some probiotics and fortified foods. Unique IS2, MTCC 5856, and BC99 are different strains, or varieties, of this bacterium. They were studied separately.

Double-check the conclusions and consult the sources before choosing a supplement.

Main conclusion

Potential benefits

  • In adults with regular bloating and gas, strain MTCC 5856 reduced the combined bloating, belching, and gas score by 5.85 points over four weeks, versus 1.09 with placebo.
  • In adults with irritable bowel syndrome and infrequent stools, strain Unique IS2 reduced the abdominal pain score more than placebo over eight weeks.
  • In healthy adults with infrequent stools, Unique IS2 improved the stool consistency score over four weeks; no convincing increase in stool frequency compared with placebo was found.
  • In adults with sleep complaints, sleep duration during an overnight examination increased by an average of about 50 minutes after four weeks of IDCC 1201; there was no convincing increase with placebo.
  • In adults with overweight or obesity, no additional reduction in body weight with BC99 compared with placebo was found over eight weeks.
  • In young men with resistance-training experience, Unique IS2 together with whey protein helped improve leg press results and jump height more than protein with placebo over 60 days; both groups followed the same resistance-training program.

[1] [2] [3] [4] [5] [6]

What was studied

  • In Japanese women complaining of rough skin and infrequent stools, SANK70258 showed no convincing advantage for roughness, scaling, or water loss through the skin over eight weeks.
  • Gas and digestive discomfort are possible. With severe illness or weakened immunity, discuss the choice of a live probiotic with a doctor because of infection risk.
  • In the sports study, both groups received milk whey powder containing lactose. With milk protein allergy or lactose intolerance, check the product’s full composition.

[1] [2] [3] [4]

Forms studied

  • Digestion studies used MTCC 5856 at 2 billion viable spores per tablet and Unique IS2 at 2 billion CFU per capsule daily. CFU denotes the number of viable microorganisms.
  • The sleep study used an IDCC 1201 capsule containing 5 billion CFU one hour before bed for four weeks; the weight study used a BC99 sachet containing 5 billion CFU daily for eight weeks.
  • On the label, look for the full strain code, CFU count at the end of shelf life, and storage conditions. Inactivated cells are a separate ingredient without live bacteria.

[1] [2] [3] [4] [5] [6]

How to get it from food

  • Spores of strain GBI-30, 6086 may be added to drinks, juices, dairy products, and their plant-based alternatives.
  • This strain may also be added to breakfast foods and baked goods. Check the label for the presence of the culture and its amount in a particular product.

[1] [2]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Abdominal pain in IBS — Unique IS2Pain on a scale from 0 to 10 fell from 8.2 to 3.4 points with the supplement and from 8.3 to 6.7 with placebo. The between-group difference had a p-value of <0.001.
1/4 Very lowOne study. The analysis excluded 28 of the 136 assigned participants. Different sections of the article report different pain scores. The figures here come from the week 8 findings in the Results section. This discrepancy accounts for the very low confidence in the conclusion.
11 publication describedRandomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults ↗136 adults aged 18–60 with irritable bowel syndrome (IBS) and fewer than three bowel movements per week that felt complete, without laxatives. Of the 108 participants who completed the study, 53 took the supplement and 55 took placebo. People with diarrhea-predominant IBS were excluded.
  1. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults ↗
Stool frequency — Unique IS2Stool frequency did not increase more than with placebo. The mean change was +0.05 versus +0.04 bowel movements per day (p=0.551).
2/4 LowOne four-week study with mostly women. Stool frequency was recorded in a diary. Stool frequency changed slightly within the supplement group, without an advantage over placebo.
11 publication describedBacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗Healthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded.
  1. Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗
Stool consistency — Unique IS2Stool consistency improved. The score fell by 0.31 points with the supplement and rose by 0.04 points with placebo (p=0.018). The authors converted Bristol Stool Scale types to a score from 1 to 4, with lower scores indicating more favorable consistency.
2/4 LowOne short study with mostly women. Stool consistency differed between groups at baseline. The authors accounted for baseline scores in the comparison.
11 publication describedBacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗Healthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded.
  1. Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Forms

Strain and live bacterial count — Unique IS2, MTCC 5856, IDCC 1201, BC99, and SANK70258 have been studied separately. When choosing a product, look for the full strain name, the CFU count at the end of shelf life, and the storage instructions on the label. A higher CFU count alone does not imply a greater effect. Live and nonliving cells — Inactivated cells contain no live bacteria. Their cell count cannot be treated as a dose of live probiotic, and findings from trials of live strains cannot be applied to them. Use in strength training — Unique IS2 was studied alongside 20 g of whey powder daily and strength training. The available description does not specify whether the probiotic itself was supplied as a capsule or powder.

Guidance for each goal

Abdominal pain in IBS — Unique IS21/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne study. The analysis excluded 28 of the 136 assigned participants. Different sections of the article report different pain scores. The figures here come from the week 8 findings in the Results section. This discrepancy accounts for the very low confidence in the conclusion.

Pain decreased more than with placebo.

Study findings. Pain on a scale from 0 to 10 fell from 8.2 to 3.4 points with the supplement and from 8.3 to 6.7 with placebo. The between-group difference had a p-value of <0.001.

Studied regimen2 billion CFU in one capsule daily, after a mealUnique IS2 capsule containing viable spores
Duration and population8 weeks136 adults aged 18–60 with irritable bowel syndrome (IBS) and fewer than three bowel movements per week that felt complete, without laxatives. Of the 108 participants who completed the study, 53 took the supplement and 55 took placebo. People with diarrhea-predominant IBS were excluded.

Comparator — Maltodextrin placebo capsule

Stool frequency — Unique IS22/4 LowRead moreCollapse
Confidence
2/4 LowOne four-week study with mostly women. Stool frequency was recorded in a diary. Stool frequency changed slightly within the supplement group, without an advantage over placebo.

There was no advantage for stool frequency.

Study findings. Stool frequency did not increase more than with placebo. The mean change was +0.05 versus +0.04 bowel movements per day (p=0.551).

Studied regimen2 billion CFU in one capsule daily, with or without foodUnique IS2 oral capsule
Duration and population4 weeks after a 2-week placebo run-inHealthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded.

Comparator — Matching placebo capsule

Stool consistency — Unique IS22/4 LowRead moreCollapse
Confidence
2/4 LowOne short study with mostly women. Stool consistency differed between groups at baseline. The authors accounted for baseline scores in the comparison.

Stool consistency improved.

Study findings. Stool consistency improved. The score fell by 0.31 points with the supplement and rose by 0.04 points with placebo (p=0.018). The authors converted Bristol Stool Scale types to a score from 1 to 4, with lower scores indicating more favorable consistency.

Studied regimen2 billion CFU in one capsule daily, with or without foodUnique IS2 oral capsule
Duration and population4 weeks after a 2-week placebo run-inHealthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded.

Comparator — Matching placebo capsule

Digestive quality of life — Unique IS22/4 LowRead moreCollapse
Confidence
2/4 LowOne four-week study involving mostly women without a diagnosed bowel disease. The authors reported no statistically significant difference between groups and provided neither the size of the difference nor its confidence interval.

There was no advantage for quality of life.

Study findings. Digestive quality of life did not improve more than with placebo. The between-group difference in changes on the adapted GIQLI questionnaire was statistically nonsignificant (p>0.05). The authors did not report the size of the difference.

Studied regimen2 billion CFU in one capsule daily, with or without foodUnique IS2 oral capsule
Duration and population4 weeks after a 2-week placebo run-inHealthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded.

Comparator — Matching placebo capsule

Digestive symptoms — Unique IS22/4 LowRead moreCollapse
Confidence
2/4 LowOne four-week study involving mostly women without a diagnosed bowel disease. The authors reported no statistically significant difference between groups and provided neither the size of the difference nor its confidence interval.

There was no advantage for the reported symptoms.

Study findings. Digestive symptoms, measured using the relevant section of the GIQLI questionnaire, did not improve more than with placebo (p>0.05). The authors did not report the size of the difference.

Studied regimen2 billion CFU in one capsule daily, with or without foodUnique IS2 oral capsule
Duration and population4 weeks after a 2-week placebo run-inHealthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded.

Comparator — Matching placebo capsule

Bloating, belching, and gas — MTCC 58562/4 LowRead moreCollapse
Confidence
2/4 LowOne small study that analyzed 66 of 70 participants. The study assessed several subjective symptoms. This result applies to bloating, belching, and gas in the group studied.

Bloating, belching, and gas decreased.

Study findings. The combined score for bloating, belching, and gas on a scale from 0 to 18 fell from 8.91 to 3.06 points with the supplement and from 9.42 to 8.33 with placebo. The decreases were 5.85 versus 1.09 points (p<0.001).

Studied regimen2 billion viable spores in one tablet daily, 30 minutes before the morning mealMTCC 5856 (LactoSpore), a 410 mg tablet containing viable spores
Duration and population4 weeks, with final assessment on day 3070 adults aged 18–65 with recurring bloating and gas. Of these, 66 completed the study, 33 in each group. People with IBS, functional constipation, lactose intolerance, or functional dyspepsia were excluded.

Comparator — Placebo tablet containing maltodextrin and the same excipients

Percentage of time asleep during overnight testing — IDCC 12012/4 LowRead moreCollapse
Confidence
2/4 LowOne four-week study. At baseline, the probiotic group slept worse than the placebo group. Sleep was measured objectively during overnight testing before and after supplementation. The reported change reflects those assessments and gives no estimate of the average change across nights at home. The advantage in the percentage of time asleep persisted after adjustment for baseline differences.

The percentage of time asleep increased.

Study findings. During overnight testing, the percentage of time asleep rose from 75.75% to 89.46% with the supplement and went from 85.08% to 84.93% with placebo, a change of +13.71 versus −0.15 percentage points. The difference persisted after adjustment for baseline values (p=0.015).

Studied regimen5 billion CFU in one capsule daily, one hour before bedtimeIDCC 1201 capsule containing live bacteria
Duration and population4 weeks80 adults aged 19–65 with sleep complaints, a PSQI sleep quality score of ≥5, and an ISI insomnia score of 8–21. Of these, 78 completed the study, 39 in each group. People with severe insomnia or diagnosed sleep apnea were excluded.

Comparator — Matching maltodextrin placebo capsule

Sleep duration during overnight testing — IDCC 12012/4 LowRead moreCollapse
Confidence
2/4 LowOne four-week study. At baseline, the probiotic group slept worse than the placebo group. Sleep duration was an additional outcome. It was measured during overnight testing before and after supplementation. The reported change reflects those assessments and gives no estimate of the average change across nights at home.

Participants slept longer during overnight testing.

Study findings. Sleep duration during overnight testing increased by an average of 49.56 minutes with the supplement and decreased by 0.50 minutes with placebo (p=0.002). At baseline, the supplement group slept an average of 272.88 minutes and the placebo group slept 306.25 minutes.

Studied regimen5 billion CFU in one capsule daily, one hour before bedtimeIDCC 1201 capsule containing live bacteria
Duration and population4 weeks80 adults aged 19–65 with sleep complaints, a PSQI sleep quality score of ≥5, and an ISI insomnia score of 8–21. Of these, 78 completed the study, 39 in each group. People with severe insomnia or diagnosed sleep apnea were excluded.

Comparator — Matching maltodextrin placebo capsule

Body weight — BC992/4 LowRead moreCollapse
Confidence
2/4 LowOne small study. Body weight and blood lipid measures were additional outcomes. The conclusion applies to all participants combined. A result from one subgroup cannot be generalized to the entire sample.

There was no additional weight loss.

Study findings. Body weight fell in both groups, with no advantage for BC99 over placebo. It fell from 82.53 to 80.39 kg with BC99 and from 80.80 to 78.51 kg with placebo. The changes were −2.14 and −2.29 kg, respectively.

Studied regimen5 billion CFU daily while participants maintained their usual diet and physical activityBC99 single-serving sachet containing live bacteria and 3 g of maltodextrin
Duration and population8 weeks66 adults aged 18–65 with overweight or obesity in China, 33 in each group. Each group included 20 participants with overweight and 13 with obesity.

Comparator — Sachet containing 3 g of maltodextrin

Blood cholesterol and triglycerides — BC992/4 LowRead moreCollapse
Confidence
2/4 LowOne small study. Body weight and blood lipid measures were additional outcomes. The conclusion applies to all participants combined. A result from one subgroup cannot be generalized to the entire sample.

The supplement showed no advantage over placebo for cholesterol or triglycerides.

Study findings. In the full sample, there was no benefit over placebo for total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides.

Studied regimen5 billion CFU daily while participants maintained their usual diet and physical activityBC99 single-serving sachet containing live bacteria and 3 g of maltodextrin
Duration and population8 weeks66 adults aged 18–65 with overweight or obesity in China, 33 in each group. Each group included 20 participants with overweight and 13 with obesity.

Comparator — Sachet containing 3 g of maltodextrin

Leg press strength — Unique IS2 with protein and training2/4 LowRead moreCollapse
Confidence
2/4 LowOne study. Of the 70 assigned participants, 56 completed the protocol. The study assessed the effect alongside whey protein and training. The changes were estimated from a graph in the original article.

Leg press strength increased more with the supplement.

Study findings. The one-repetition maximum on the leg press increased by about 24 kg with the supplement and 14 kg with placebo. These values were estimated from the graph. The abstract reports a between-group p-value of 0.024.

Studied regimen2 billion CFU daily alongside 20 g of whey powder containing 15.4 g of proteinOral Unique IS2 taken with whey protein
Duration and population60 days70 men with strength-training experience, with an average age of 21, were assigned to two groups of 35. Of these, 56 completed the protocol, 28 in each group. Both groups followed the same strength-training program.

Comparator — The same whey powder and training, with lactose in place of the probiotic

Vertical jump height — Unique IS2 with protein and training2/4 LowRead moreCollapse
Confidence
2/4 LowOne study. Of the 70 assigned participants, 56 completed the protocol. The study assessed the effect alongside whey protein and training. The changes were estimated from a graph in the original article.

Jump height increased more with the supplement.

Study findings. Vertical jump height increased by about 9 cm with the supplement and 4.5 cm with placebo. These values were estimated from the graph. The abstract reports a between-group p-value of 0.007.

Studied regimen2 billion CFU daily alongside 20 g of whey powder containing 15.4 g of proteinOral Unique IS2 taken with whey protein
Duration and population60 days70 men with strength-training experience, with an average age of 21, were assigned to two groups of 35. Of these, 56 completed the protocol, 28 in each group. Both groups followed the same strength-training program.

Comparator — The same whey powder and training, with lactose in place of the probiotic

Skin roughness — SANK702582/4 LowRead moreCollapse
Confidence
2/4 LowOne small study with several skin measures. The analysis included 75 of the 80 women in the study. The women were specifically selected based on skin and bowel characteristics. Individual subgroup findings cannot substitute for the result across all women in the study.

There was no advantage for skin roughness.

Study findings. Instrument-measured skin roughness did not improve more than with placebo. The SEr measure changed by +0.26 versus +0.13 on the forehead (p=0.569) and −0.20 versus +0.02 at the outer corners of the eyes (p=0.415).

Studied regimen1 billion CFU in one capsule dailySANK70258 capsule containing 67 mg of a bacterial culture preparation
Duration and population8 weeks80 Japanese women aged 30–65, selected based on self-reported skin roughness, infrequent bowel movements, and gut microbiota measures. The primary analysis included 75 women, 39 on the supplement and 36 on placebo.

Comparator — Matching placebo capsule

Skin flaking — SANK702582/4 LowRead moreCollapse
Confidence
2/4 LowOne small study with several skin measures. The analysis included 75 of the 80 women in the study. The women were specifically selected based on skin and bowel characteristics. Individual subgroup findings cannot substitute for the result across all women in the study.

There was no advantage for skin flaking.

Study findings. Instrument-measured skin flaking did not decrease more than with placebo. The SEsc measure changed by −0.03 versus +0.01 on the forehead (p=0.428) and −0.05 versus −0.02 at the outer corners of the eyes (p=0.605).

Studied regimen1 billion CFU in one capsule dailySANK70258 capsule containing 67 mg of a bacterial culture preparation
Duration and population8 weeks80 Japanese women aged 30–65, selected based on self-reported skin roughness, infrequent bowel movements, and gut microbiota measures. The primary analysis included 75 women, 39 on the supplement and 36 on placebo.

Comparator — Matching placebo capsule

Water loss through the skin — SANK702582/4 LowRead moreCollapse
Confidence
2/4 LowOne small study with several skin measures. The analysis included 75 of the 80 women in the study. The women were specifically selected based on skin and bowel characteristics. Individual subgroup findings cannot substitute for the result across all women in the study.

There was no advantage for moisture loss.

Study findings. Water loss through the skin did not decrease more than with placebo. The change was −0.58 versus −0.53 g/m²·h on the forearm (p=0.880) and +0.60 versus −0.80 g/m²·h at the outer corners of the eyes (p=0.216).

Studied regimen1 billion CFU in one capsule dailySANK70258 capsule containing 67 mg of a bacterial culture preparation
Duration and population8 weeks80 Japanese women aged 30–65, selected based on self-reported skin roughness, infrequent bowel movements, and gut microbiota measures. The primary analysis included 75 women, 39 on the supplement and 36 on placebo.

Comparator — Matching placebo capsule

Skin lightness — SANK702582/4 LowRead moreCollapse
Confidence
2/4 LowOne small study with several skin measures. The analysis included 75 of the 80 women in the study. The change in skin lightness was measured with an instrument. The study did not establish how noticeable the change was to the eye.

The instrument detected slight skin lightening.

Study findings. Instrument-measured skin lightness (L*) increased by 0.55 units with the supplement and decreased by 0.05 units with placebo (p=0.040). Higher values indicate a lighter skin tone. The study did not assess whether the change was visible.

Studied regimen1 billion CFU in one capsule dailySANK70258 capsule containing 67 mg of a bacterial culture preparation
Duration and population8 weeks80 Japanese women aged 30–65, selected based on self-reported skin roughness, infrequent bowel movements, and gut microbiota measures. The primary analysis included 75 women, 39 on the supplement and 36 on placebo.

Comparator — Matching placebo capsule

Safety and limitations

Gas and digestive discomfort can occur. In the MTCC 5856 study, brief heartburn and nausea were noted in one participant. In the sports study, one participant in the supplement group withdrew because of vomiting and loose stools. There was also a withdrawal in the placebo group because of vomiting and discomfort. These events alone do not establish that the probiotic caused them. If you are seriously ill or have a weakened immune system, discuss your choice of live probiotic with a doctor. Infections associated with probiotic microorganisms have been reported in vulnerable people. Preterm infants are particularly vulnerable. These risks apply to probiotics generally. This review does not estimate how often they occur with any specific strain. The sports study used whey protein derived from milk. The powder contained lactose, and lactose was added in place of the probiotic in the comparison group. If you have a milk protein allergy or lactose intolerance, check the full ingredient list.

The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study ↗ · The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study ↗ · Probiotics — Health Professional Fact Sheet (NIH ODS) ↗

Interactions

WithEffectActionSource
AntibioticsSome antibiotics may reduce the effects of some probiotics. This depends on the specific drug and microorganism.Ask a doctor or pharmacist about compatibility and when to take your chosen product. No single interval applies to every combination.NIH Office of Dietary Supplements: Dietary Supplements for Immune Function and Infectious Diseases — Health Professional Fact Sheet ↗

Food sources

GBI-30, 6086 spores may be added to beverages, juices, dairy products, plant-based dairy alternatives, breakfast foods, and baked goods. Check the label to see whether the culture is present and in what amount. A product name such as yogurt alone does not indicate that it contains this strain. The GBI-30, 6086 strain used in foods differs from the strains in the results table. This bacterium has no established daily dietary intake recommendation or general tolerable upper intake level. Amounts in foods and doses used in individual trials do not establish either benchmark.

FDA GRAS Notice No. 399: Bacillus coagulans GBI-30, 6086 spores ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults ↗Abdominal pain in IBS — Unique IS2136 adults aged 18–60 with irritable bowel syndrome (IBS) and fewer than three bowel movements per week that felt complete, without laxatives. Of the 108 participants who completed the study, 53 took the supplement and 55 took placebo. People with diarrhea-predominant IBS were excluded.Unique IS2 capsule containing viable spores. Participants took 2 billion CFU in one capsule daily after a meal for 8 weeks. Comparator — Maltodextrin placebo capsulePain decreased more than with placebo.
Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗Stool frequency — Unique IS2 / Stool consistency — Unique IS2 / Digestive quality of life — Unique IS2 / Digestive symptoms — Unique IS2Healthy adults aged 18–65 who had at least three but fewer than seven bowel movements per week that felt complete, without laxatives. The study assigned 145 participants and included 143 in the primary analysis (72 on the supplement and 71 on placebo). People with IBS or functional constipation were excluded.Unique IS2 oral capsule. Participants took 2 billion CFU in one capsule daily, with or without food, for 4 weeks after a 2-week placebo run-in. Comparator — Matching placebo capsuleThere was no advantage for stool frequency. Stool consistency improved. There was no advantage for quality of life or for the reported symptoms.

Sources

Sources
  1. Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults ↗
  2. Bacillus coagulans Unique IS2 improves stool characteristics in healthy adults with infrequent bowel movements: a randomized, double-blind, placebo-controlled trial ↗
  3. The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study ↗
  4. Efficacy and Safety of Bacillus coagulans IDCC 1201 for Sleep Improvement in Adults with Sleep Disturbance: A Randomized, Double-Blind, Placebo-Controlled Polysomnographic Study ↗
  5. Effect of Bacillus coagulans BC99 supplementation on body weight and gut microbiota in overweight and obese individual: a randomized, double-blind, placebo-controlled study ↗
  6. The effect of Bacillus coagulans Unique IS-2 supplementation on plasma amino acid levels and muscle strength in resistance trained males consuming whey protein: a double-blind, placebo-controlled study ↗
  7. Improvement of skin condition and intestinal microbiota via Heyndrickxia coagulans SANK70258 intake: A placebo-controlled, randomized, double-blind, parallel-group comparative study ↗
  8. Probiotics — Health Professional Fact Sheet (NIH ODS) ↗
  9. FDA GRAS Notice No. 399: Bacillus coagulans GBI-30, 6086 spores ↗
  10. GRAS Notice 670: Inactivated Bacillus coagulans GBI-30, 6086 ↗
  11. NIH Office of Dietary Supplements: Dietary Supplements for Immune Function and Infectious Diseases — Health Professional Fact Sheet ↗